Trevi Therapeutics, Inc. Common Stock
Here’s whether Trevi Therapeutics, Inc. Common Stock (TRVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.21% over 10 days); strong 1-year return of +149.7%; 3-month momentum positive (+45.3%); rising volume confirms the move (1.20x 30d avg). Concerns: RSI 88 — overbought, elevated pullback risk. Currently 3.4% off its 52-week high. Score: +6/7.
TRVI is in a confirmed uptrend, trading above both its 50-day ($11.83) and 200-day ($10.29) moving averages. With an RSI of 87.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +149.7% compares to +35.1% for SPY (beat the market by 114.6%).